Haefner M, Bluethner T, Niederhagen M, Moebius C, Wittekind C, Mossner J, Caca K, Wiedmann M. Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors. World J Gastroenterol 2008; 14(23): 3681-3692
Corresponding Author of This Article
Dr. Marcus Wiedmann, Department of Internal Medicine II, University of Leipzig, Philipp-Rosenthal-Str. 27, Leipzig 04103, Germany. firstname.lastname@example.org
Article-Type of This Article
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Jun 21, 2008; 14(23): 3681-3692 Published online Jun 21, 2008. doi: 10.3748/wjg.14.3681
Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors
Martin Haefner, Thilo Bluethner, Manuel Niederhagen, Christian Moebius, Christian Wittekind, Joachim Mossner, Karel Caca, Marcus Wiedmann
Martin Haefner, Thilo Bluethner, Joachim Mossner, Marcus Wiedmann, Department of Internal Medicine II, University of Leipzig, Philipp-Rosenthal-Str. 27, Leipzig 04103, Germany
Manuel Niederhagen, Christian Wittekind, Institute of Pathology, University of Leipzig, Liebigstr. 26, Leipzig 04103, Germany
Christian Moebius, Department of Surgery II, University of Leipzig, Liebigstrasse 20a, Leipzig 04103, Germany
Karel Caca, Department of Internal Medicine I, Klinikum Ludwigsburg, Posilipostr. 4, Ludwigsburg 71640, Germany
ORCID number: $[AuthorORCIDs]
Author contributions: Wiedmann M and Caca K designed research; Haefner M, Bluethner T and Niederhagen M performed research; Wittekind C contributed analytic tools; Moebius C and Mossner J analyzed data and corrected the manuscript; and Wiedmann M wrote the paper.
Correspondence to: Dr. Marcus Wiedmann, Department of Internal Medicine II, University of Leipzig, Philipp-Rosenthal-Str. 27, Leipzig 04103, Germany. email@example.com
Received: January 25, 2008 Revised: May 4, 2008 Accepted: May 11, 2008 Published online: June 21, 2008
AIM: To investigate in vitro and in vivo treatment with histone deacetylase inhibitors NVP-LAQ824 and NVP-LBH589 in pancreatic cancer.
METHODS: Cell-growth inhibition by NVP-LAQ824 and NVP-LBH589 was studied in vitro in 8 human pancreatic cancer cell lines using the 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. In addition, the anti-tumoral effect of NVP-LBH589 was studied in a chimeric mouse model. Anti-tumoral activity of the drugs was assessed by immunoblotting for p21WAF-1, acH4, cell cycle analysis, TUNEL assay, and immunohistochemistry for MIB-1.
RESULTS: In vitro treatment with both compounds significantly suppressed the growth of all cancer cell lines and was associated with hyperacetylation of nucleosomal histone H4, increased expression of p21WAF-1, cell cycle arrest at G2/M-checkpoint, and increased apoptosis. In vivo, NVP-LBH589 alone significantly reduced tumor mass and potentiated the efficacy of gemcitabine. Further analysis of the tumor specimens revealed slightly increased apoptosis and no significant reduction of cell proliferation.
CONCLUSION: Our findings suggest that NVP-LBH589 and NVP-LAQ824 are active against human pancreatic cancer, although the precise mechanism of in vivo drug action is not yet completely understood. Therefore, further preclinical and clinical studies for the treatment of pancreatic cancer are recommended.
Citation: Haefner M, Bluethner T, Niederhagen M, Moebius C, Wittekind C, Mossner J, Caca K, Wiedmann M. Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors. World J Gastroenterol 2008; 14(23): 3681-3692
Pancreatic cancer is the fifth to sixth leading cause of cancer death in Europe and the fourth leading cause of cancer death in the USA. The lethality of this malignancy is demonstrated by the fact that the annual incidence is approximately equal to the annual deaths. Unfortunately, carcinoma of the pancreas is increasing in incidence, and its risk factors are poorly understood. Although surgical resection remains the only chance for cure, less than 10% of patients diagnosed with pancreatic cancer are eligible for curative (R0) resection, since up to 90% of patients will present with locally advanced or metastatic disease. In addition, there is a high rate of relapse, even in patients who receive adjuvant therapy. A recent evaluation of the Finnish Cancer Registry, which recorded 4922 pancreatic cancer patients between 1990 and 1996, detected only 89 five year survivors (1.8%). Metastatic cancer tends to be a rapidly progressing disease, often accompanied by significant weight loss, abdominal pain, nausea, and/or depression. For decades, 5-fluorouracil (5-FU) was the most widely used chemotherapeutic agent in metastatic pancreatic cancer. Today gemcitabine, a nucleoside analogue that is incorporated into replicating DNA resulting in premature chain termination and apoptosis, is the current standard of care. In a phase III approval study 126 patients with metastatic disease who had not received prior chemotherapy were randomized to weekly gemcitabine (n = 63) or weekly bolus 5-FU (n = 63). Overall survival in patients treated with gemcitabine was significantly improved compared with patients treated with 5-FU; However, there was no convincing gain in median survival time (median survival 5.7 mo vs 4.4 mo, P = 0.0025). The primary efficacy measure in this study was clinical benefit response, a composite of patient-oriented parameters including pain, Karnofsky performance status, daily analgesic usage, and body weight. Clinical benefit was experienced in 23.8% of patients treated with gemcitabine compared with only 4.5% of the patients treated with 5-FU (P = 0.022). Fixed-dose-rate (FDR) gemcitabine (1500 mg/m2 at 10 mg/m2 per minute) has also been investigated by Tempero et al in comparison to 2200 mg/m2 gemcitabine over 30 min. Although median survival time improved from 5.0 mo in the standard arm to 8.0 mo in the FDR arm (P = 0.013), grade 3 and 4 toxicity increased significantly. Many combination regimens with gemcitabine have been tested in open-label phase II or III studies with higher response and progression-free survival rates, but no definitive benefit in overall survival, with the only exception being a combination with capecitabine. As little progress has been made in the past decade, new strategies should focus on targeting cancer cells at the molecular level. Recently, in a randomized phase III placebo-controlled trial, Moore et al demonstrated that combining gemcitabine with EGFR inhibitor erlotinib was associated with a modest, but statistically significant survival benefit of 15 d. In contrast, a recent phase III trial (SWOG S0205 study) failed to demonstrate a clinically significant advantage of the addition of cetuximab, an anti-EGFR monoclonal antibody, to gemcitabine for overall survival, progression free survival and response. Another approach is targeting VEGF as a key player in tumor growth and resistance to therapy. In a phase II trial with 52 patients, a combination of VEGF inhibitor bevacizumab and gemcitabine yielded a 21% response rate and a median survival of 8.8 mo. These data led CALGB to conduct a randomized, double-blind, placebo-controlled, phase III trial (CALGB 80303). However, the addition of bevacizumab to gemcitabine did not improve survival. Inhibiting histone deacetylases (HDACs), which regulate interactions between histones and DNA together with histone acetylases (HATs) as counter-players, may be another promising molecular target. Clinical studies published so far have shown that HDAC inhibitors (HDACIs) can be administered safely in humans and that treatment of some cancers with such agents seems to be beneficial. NVP-LAQ824 and NVP-LBH589 are new chemical entities belonging to a structurally novel class of cinnamic hydroxamic acid compounds[14–17], which are currently in phase I clinical evaluation in advanced refractory solid tumors and hematologic malignancies[18–22]. However, little is known about their potential efficacy in pancreatic cancer. Therefore, the objectives of the current study were to investigate the efficacy of in vitro and in vivo treatment with the novel pan-HDAC inhibitors NVP-LAQ824 and NVP-LBH589 and to evaluate effects of combination with gemcitabine.
MATERIALS AND METHODS
Eight human pancreatic cancer cell lines (Hs766T, As-PC-1, CFPAC-1, Capan-2, Panc-1, MiaPaca-2, HPAF-2 and L3.6pl) were examined[23–27]. All cell lines were cultured in a 37°C incubator with 50-100 mL/L CO2 in appropriate media. The HDACIs NVP-LAQ824 and NVP-LBH589 were provided by Novartis (Basel, Switzerland) and dissolved in dimethyl sulfoxide (DMSO) (10 mmol/L stock). Hoechst dye, sodium butyrate and monoclonal (mc) β-actin antibody were purchased from Sigma (Sigma-Aldrich Chemie GmbH Munich, Germany), mc p21WAF-1/Cip-1 from Cell Signaling (Cell Signaling Technology, Beverly, USA), mc acH4 antibody from Upstate (Upstate Biotechnology, Lake Placid, USA), mc MIB-1 antibody from Dako (Glostrub, Denmark), and gemcitabine (diluted in D5W and 50 mL/L DMSO) from our hospital pharmacy. Six to eight-wk-old female athymic NMRI nude mice were supplied by Taconic (Taconic Europe, Ry, Denmark) and held under pathogen-free conditions. Humane care was administered, and study protocols complied with the institutional guidelines.
Inhibition of cell growth
Cytotoxic effects of both drugs were determined by the 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma-Aldrich Chemie GmbH Munich, Germany) assay. 1-5 × 103 cells were seeded in triplicate in 96-well plates (100 &mgr;L/well) and allowed to attach overnight. The medium was then replaced with media (100 &mgr;L) containing the designated drug or vehicle control (50 mL/L DMSO in D5W) followed by an incubation for 3 or 6 d. For the 6 d experiment, medium was changed after 3 d. Three hours before the end of the incubation period, 10 &mgr;L of PBS containing MTT (5 g/L) was added to each well. Following this, the medium was removed. The precipitate was then resuspended in 100 &mgr;L of lysis buffer (DMSO, 100 g/L SDS). Absorbance was measured on a plate reader at 590 nm using a reference wavelength of 630 nm. Each experiment was performed in triplicate.
Cell culture monolayers were washed twice with ice-cold PBS and lysed with RIPA-buffer containing Tris-HCl (50 mmol/L, pH 7.4), NP-40 (10 g/L), sodium-desoxycholate (2.5 g/L), NaCl (150 mmol/L), EDTA (1 mmol/L), sodium-orthovanadate (1 mmol/L), and one tablet of complete mini-EDTA-free protease inhibitor cocktail (Boehringer, Mannheim, Germany, in 10 mL buffer). Histones for anti-acH4 immunoblotting were isolated by acid extraction [cells were lysed in ice-cold lysis buffer (HEPES 10 mmol/L; pH 7.9), MgCl2 (1.5 mmol/L), KCl (10 mmol/L), DTT (0.5 mmol/L), PMSF (1.5 mmol/L), and additional protease inhibitor]. One molar HCl was added to a final concentration of 0.2 mol/L, followed by an incubation on ice for 30 min and centrifugation at 13 000 r/min for 10 min. The supernatant was retained and dialysed against 200 mL of 0.2 mol/L acetic acid twice for 1 h and against 200 mL H2O overnight). Proteins were quantified by Bradford protein assay (Bio-Rad, Munich, Germany) and stored at -80°C. 50 &mgr;g of cell or tissue lysates were separated on SDS-polyacrylamide gels and electroblotted onto polyvinylidene difluoride membranes (Amersham Pharmacia Biotech, Freiburg, Germany). Membranes were then incubated in blocking solution [50 g/L dry milk in 10 mmol/L Tris-HCl, 140 mmol/L NaCl, 1 g/L Tween-20 (TBS-T)], followed by incubation with the primary antibody at 4°C overnight (50 g/L BSA in TBS-T). The membranes were then washed in TBS-T and incubated with horseradish peroxidase (HRPO)-conjugated secondary antibodies for 1 h at room temperature. Antibody detection was performed with an enhanced chemoluminescence reaction (SuperSignal West Dura, Pierce, Rockford, USA).
Cell cycle analysis
Cells were seeded in T-25 flasks (2 × 105), treated with various concentrations of NVP-LAQ824 or NVP-LBH589 or vehicle control (50 mL/L DMSO in D5W) for 72 h, washed with PBS, trypsinized, centrifuged, and fixed in 750 mL/L ice-cold ethanol-phosphate-buffered saline containing 10 g/L EDTA. DNA was labeled with 100 mL/L propidium iodide. Cells were sorted by FACScan analysis, and cell cycle profiles were determined using ModFitLT V2.0 software (Becton Dickinson, San Diego, USA). Each experiment was performed in triplicate.
Tumors were induced by injecting 5 × 106 HPAF-2 or L3.6pl cells in 200 &mgr;L PBS sc into the flank region of NMRI nude mice. Treatment was started when an average tumor volume of 150 mm³ was reached (usually after 2 wk). The verum groups received either NVP-LBH589 (25 mg/kg, 5 × weekly) or gemcitabine (5 mg/kg, 1 × weekly) or a combination of both (NVP-LBH589 at 25 mg/kg, 5 × weekly plus gemcitabine at 5 mg/kg, 1 × weekly) ip, whereas the control group received placebo (carrier solution 50 mL/L DMSO in D5W) only. Treatment was continued for 28 consecutive days, tumors were measured daily with a Vernier caliper and tumor volumes were calculated using the formula tumor volume = 0.5 ×L×W², where L represents the length and W the width of the tumor. When treatment was finished, animals were sacrificed and tumors excised and weighed.
TUNEL POD test
Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (in situ cell death detection kit, POD) was used to detect apoptosis in paraffin sections from mouse tumor tissue. TUNEL was carried out following the manufacturer’s instructions (Roche, Penzberg, Germany) as previously described. Apoptotic cells (red) were counted under a light microscope after fluorescence signal conversion using peroxidase-conjugated antibody and peroxidase substrate (DAB, Roche, Penzberg, Germany). The number of positive cells was counted by an experienced pathologist (M.N.) in a total of 8 high power fields (HPFs) and expressed as mean percentage of total cells in these fields of the tumor. Necrotic tumor cells were excluded from the cell count.
For MIB-1 staining, we used paraffin sections following a protocol that has been described elsewhere. The number of positive cells was counted by an experienced pathologist (M.N.) in a total of 4 HPFs and expressed as mean percentage of total cells in these fields of the tumor.
Statistical calculations were performed using SPSS, version 10.0 (SPSS Inc., Chicago, USA). Numeric data were presented as mean value with SD or SEM. Inter-group comparisons were performed with the Student t-test and ANOVA. P < 0.05 was considered significant.
Inhibition of cell growth
After 3 d of incubation, 7 of 8 tested cell lines were sensitive to NVP-LAQ824 (mean IC50 (3 d) = 0.18 ± 0.24 &mgr;mol/L) and even more to NVP-LBH589 (mean IC50 (3 d) = 0.09 ± 0.14 &mgr;mol/L). Only cell line Capan-2 demonstrated an IC50 (3 d) value > 1 &mgr;mol/L for both compounds. Inhibition of cell growth was more pronounced if incubation time was extended to 6 d with a mean IC50 value of 0.06 ± 0.07 &mgr;mol/L for NVP-LAQ824 and 0.03 ± 0.02 &mgr;mol/L for NVP-LBH589. After 6 d of incubation, cell line Capan-2 also became responsive (Figure 1 and Table 1). In addition, DMSO alone (the solvent for NVP-LAQ824 and NVP-LBH589) had no influence on cell growth (data not shown).
Table 1 Inhibition of cell growth by NVP-LAQ824 and NVP-LBH589.
Figure 1 In vitro treatment of pancreatic cancer with NVP-LAQ824 and NVP-LBH589 (MTT assay).
A: 3-d incubation with NVP-LAQ824 (n = 3); B: 6-d incubation with NVP-LAQ824 (n = 3); C: 3-d incubation with NVP-LBH589 (n = 3); D: 6-d incubation with NVP-LBH589 (n = 3).
Treatment of cell lines HPAF-2 and L3.6pl with 0.1 &mgr;mol/L NVP-LAQ824 or 0.1 &mgr;mol/L NVP-LBH589 for 24 h resulted in acetylation of histone H4 (Figure 2A and B). The same treatment caused an induction of p21WAF-1/CIP-1 expression (Figure 2C and D). A dose increase to 0.2 &mgr;mol/L NVP-LAQ824 or NVP-LBH589 corresponded with an increase in histone H4 acetylation and p21WAF-1/CIP-1 levels. Histone H4 acetylation was higher in treated HPAF-2 than L3.6pl cells, whereas p21WAF-1/CIP-1 expression was slightly higher in treated L3.6pl cells.
Figure 2 Mechanism of drug action after in vitro treatment with NVP-LAQ824 and NVP-LBH589 for 24 h.
A and B: Acetylation of histone H4. Protein extracts from HELA cells that were treated with 5 mmol/L sodium butyrate served as positive controls; C and D: p21WAF-1/CIP-1 expression. Cell lysate from HCT 116 colon cancer cells served as positive control; A-D: Staining with β-actin antibody confirmed equal protein loading.
Cell cycle analysis
Treatment of cell lines HPAF-2 and L3.6pl with 0.1 &mgr;mol/L NVP-LAQ824 or NVP-LBH589 for 72 h resulted in G2/M arrest. This arrest was, in general, more pronounced if the dose of NVP-LAQ824 or NVP-LBH589 was increased to 0.2 &mgr;mol/L. Percentual G2/M arrest was lower for 0.2 &mgr;mol/L than 0.1 &mgr;mol/L only for the treatment of HPAF-2 cells with NVP-LBH589. This phenomenon may derive from the fact, that at the same time the sub-G1-peak was much higher for 0.2 &mgr;mol/L. For both concentrations, the effect of NVP-LBH589 was stronger than the effect of NVP-LAQ824 with the aforementioned exception of 0.2 &mgr;mol/L NVP-LBH589 in HPAF-2 cells (Figure 3). In addition, incubation with NVP-LAQ824 or NVP-LBH589 for 72 h resulted in a dose-dependent significant increase in the sub-G1-peak, which was higher for NVP-LBH589 than NVP-LAQ824 and higher in L3.6pl than in HPAF-2 cells. This result correlated well with the fact that IC50 values in the cell growth inhibition experiment (Figure 1) were lower for L3.6pl in comparison to HPAF-2 cells.
Figure 3 Cell cycle analysis.
A: Treatment of cell line HPAF-2 with 0.1 or 0.2 &mgr;mol/L NVP-LAQ824 for 72 h (n = 3); B: Treatment of cell line HPAF-2 with 0.1 or 0.2 &mgr;mol/L NVP-LBH589 for 72 h (n = 3); C: Treatment of cell line L3.6pl with 0.1 or 0.2 &mgr;mol/L NVP-LAQ824 for 72 h (n = 3); D: Treatment of cell line L3.6pl with 0.1 or 0.2 &mgr;mol/L NVP-LBH589 for 72 h (n = 3).
Chimeric mouse model
Tumors were induced in nude mice by subcutaneous injection of HPAF-2 and L3.6pl cells. These cell lines were selected because they had the best growth capability in our nude mice in a pilot study. Treatment of mice consisted of ip injections with NVP-LBH589, gemcitabine, NVP-LBH589 plus gemcitabine (COMBO) or placebo (50 mL/L DMSO in D5W). Three days after commencement of NVP-LBH589 or COMBO treatment, HPAF-2 cell tumors showed a signifi-cantly reduced volume in comparison to control (n = 7 for each group, P < 0.05). Treatment of mice with gemcitabine alone resulted in a significant reduction of tumor volume compared to control after 4 d from commencement of treatment. These differences were maintained until the end of the experiment. COMBO therapy was significantly more efficient than gemcitabine treatment alone on treatment day 7, 8, 13, 14, 15, and 16 and was significantly more efficient than NVP-LBH589 therapy alone on treatment day 7 and 14 (P < 0.05, Figure 4A). Treatment of L3.6pl tumors with NVP-LBH589 or COMBO resulted in a significantly reduced volume in comparison to control after 4 d (P < 0.05) and 3 d (P < 0.05) from commencement of therapy, respectively (n = 7 for each group). These differences were also maintained until the end of the experiment. Treatment of mice with gemcitabine alone resulted in a significant reduction of tumor volume compared to control at treatment day 12, 13, 16, 17, and 18 (P < 0.05). COMBO therapy was significantly more efficient than gemcitabine treatment alone on treatment day 3-20 and was significantly more efficient than NVP-LBH589 therapy alone on treatment day 3 (P < 0.05). NVP-LBH589 therapy was significantly more efficient than gemcitabine treatment alone on treatment day 5-20 (P < 0.05, Figure 4B). At the end of the experiment after 30 d, tumor mass in HPAF-2 cells bearing mice was significantly diminished as compared to placebo after treatment with COMBO (-63%, P < 0.05). In contrast, treatment of mice with gemcitabine (-24%, P = 0.45) or NVP-LBH589 alone (-58%, P = 0.056) did not result in any significant reduction of tumor mass as compared to control (Figure 4C). L3.6pl cell tumor mass in mice was significantly diminished after treatment with either NVP-LBH589 (-70%, P < 0.01) or COMBO (-81%, P < 0.01), but not with gemcitabine (-24%, P = 0.28), respectively. In addition, the combination of NVP-LBH589 with gemcitabine was more effective at tumor mass reduction in comparison to gemcitabine alone (P < 0.05). The L3.6pl animal experiment was stopped at day 21 for ethical reasons, since animals suffered from tumor burden. Regarding side effects of the different drugs used in HPAF-2 cell tumor bearing mice, weight loss was 2%, 0%, 13%, and 6%, in the control, gemcitabine, NVP-LBH589, and COMBO groups. There was a statistically significant difference between the control and NVP-LBH589 group (P < 0.05) and between the gemcitabine and NVP-LBH589 group (P < 0.01). Concerning side effects of the different drugs used in L3.6pl cell tumor bearing mice, weight loss was 23%, 17%, 12%, and 25%, in the control, gemcitabine, NVP-LBH589, and COMBO groups. There was a statistically significant difference between the control and NVP-LBH589 group (P < 0.05).
Figure 4 In vivo treatment with NVP-LBH589 + gemcitabine in chimeric mice.
A: Effect on tumor volume of HPAF-2 cells; B: Effect on tumor volume of L3.6pl cells; C: Effect on tumor mass (aP < 0.05, COMBO vs control; bP < 0.01, NVP-LBH589 or COMBO vs control).
In order to assess the anti-tumoral drug mechanism, paraffin sections of mouse tumors were stained with hematoxylin-eosin (H&E), MIB-1 (proliferation marker) and TUNEL (apoptosis marker) (Figure 5). Treatment with NVP-LBH589 and COMBO slightly reduced proliferation (reduced MIB-1 staining) and slightly induced apoptosis (increased TUNEL-staining) in HPAF-2 cell bearing mice, whereas proliferation was not decreased and apoptosis only slightly increased in L3.6pl cell bearing mice (Table 2).
Table 2 MIB-1- and TUNEL-staining of mouse tumor specimens.
Mean in %
Figure 5 Hematoxylin-eosin (HE), MIB-1 (proliferation marker) and TUNEL (apoptosis marker) staining of mouse tumors (SABC, x 40).
A: Cell line HPAF-2; B: Cell line L3.6pl.
Analyzing palliative treatment data, a novel approach for patients with metastatic pancreatic cancer is urgently required. Targeting HDACs may be a new option for this tumor entity. Preliminary studies have demonstrated in vitro activity of HDACIs in pancreatic cancer cell lines. Natoni et al showed that treatment with sodium butyrate, a carboxyl acid class inhibitor of HDACs, resulted in marked down-regulation of anti-apototic Bcl-xL protein expression, mitochondrial membrane depolarization, cytochrome c release from mitochondria, activation of caspase-9 and -3, and apoptosis induction. Garcia-Morales et al reported HDACIs induced apoptosis in the pancreatic cancer cell lines IMIM-PC-1, IMIM-PC-2, and RWP-1 that are normally resistant to other antineoplastic drugs. This finding was previously observed by Sato et al for five normally chemotherapy-resistant cell lines when treated with FR901228, a cyclic peptide HDACI belonging to the depsipeptides class. Recently, another class of HDACIs, the hydroxamic acids, with representatives such as trichostatin A (TSA), suberoylanilide hydroxamic acid (vorinostat, SAHA), azelaic bis-hydroxamic acid (ABHA), scriptaid, oxamflatin, pyroxamide, m-carboxycinnamic acid bis-hydroxamide (CBHA), and the recently developed NVP-LAQ824, NVP-LBH589, and PXD101 have become the focus for further research, including pancreatic cancer. Gahr et al used HDACI trichostatin A for in vitro treatment of pancreatic carcinoma cell lines YAP C and DAN G. They described an apoptosis rate of 71% and 66% after 72 h using a drug concentration of 1 &mgr;mol/L. Moore et al tested trichostatin A in PaCa44 cells using microarrays containing 22 283 probe sets. One prominent feature was the increased ratio between the levels of expression of pro-apoptotic (BIM) and anti-apoptotic (Bcl-xL and Bcl-W) genes. In addition, Cecconi et al reported for the same cell line PaCa44 that trichostatin A caused cell cycle arrest at the G2 phase and induced apoptotic cell death. Another hydroxamic acid, SAHA, induced growth inhibition in three pancreatic cell lines BxPC3, COLO-357, and PANC-1 by upregulating p21 and sequestering it in the cytoplasm. In our current study, we investigated the two novel cinnamic hydroxamic acid compounds NVP-LAQ824 and NVP-LBH589 for treatment of 8 different human pancreatic cancer cell lines. Cell-growth inhibition by NVP-LAQ824 and NVP-LBH589 was studied by MTT assay. Treatment with both compounds significantly suppressed the growth of 7 cancer cell lines after 3 d of incubation and all cancer cell lines after 6 d of incubation. We hypothezise that the lack of response of Capan-2 cells after 3 d of treatment may be based on the status of the tumor suppressor p53. A genetic profile of 10 different human pancreatic cancer cell lines (6 of the 8 cell lines used in our experiment being amongst them) created by a group from John Hopkins University (http://pathology2.jhu.edu/pancreas/geneticsweb/ profiles.htm) discovered p53 mutations in almost all cell lines, but not in Capan-2 cells. On the other hand, it has been shown that acetylation and deacetylation of p53 is likely to be part of the mechanism that controls its physiological activity. Whereas HDACs are capable of downregulating p53 function, HDAC inhibition can cause the opposite effect. Interestingly, it has also been shown that HDAC inhibitors, such as FR901228 and trichostatin A, completely deplete mutant p53 in cancer cell lines and restore p53-like functions, which is highly toxic to cell lines with mutant p53. Donadelli et al confirmed this finding in p53 gene mutated pancreatic cancer cell lines which were treated with trichostatin A. The compound induced G2 phase arrest and apoptotic cell death by activation of p21waf1, which is normally induced by p53.
In previous in vitro studies, NVP-LAQ824 exhibited potent anti-proliferative activity against colon carcinoma (IC50 = 0.01 &mgr;mol/L), and biliary tract cancer (IC50 = 0.11 &mgr;mol/L) as well as against non-small cell lung carcinoma (IC50 = 0.15 &mgr;mol/L), prostate cancer (IC50 = 0.018-0.023 &mgr;mol/L), head and neck squamous carcinoma (IC50 = 0.04-0.34 &mgr;mol/L), and human breast adenocarcinoma cells (IC50 = 0.03-0.039 &mgr;mol/L) after 72 h of exposure[1640–42]. The in vitro effects of NVP-LAQ824 on hematologic malignancies have been examined in several human cell lines with a death rate of more than 90% following 48 h of drug incubation, with exposures as low as 0.1 &mgr;mol/L[43–45]. Our second compound NVP-LBH589, was even more effective in vitro for the treatment of human chronic myeloid leukemia blast crisis K562 and LAMA-84, multiple myeloma, and acute leukemia MV4-11 cells[1546–48].
The in vitro anti-tumoral drug mechanism in our study was assessed by immunoblotting for acH4 (surrogate marker for histone acetylation) p21WAF-1/CIP-1, and cell cycle analysis. Treatment with both compounds was associated with hyperacetylation of nucleosomal histone H4, increased expression of p21WAF-1/CIP-1, cell cycle arrest at G2/M-checkpoint, and significant induction of apoptosis (increased sub-G1-peak). Therefore, our results are very consistent with the in vitro results of the aforementioned studies by Natoni et al, Garcia-Morales et al, Sato et al, Gahr et al, Donadelli et al, Cecconi et al, and Arnold et al.
Encouraged by our in vitro results, we decided to test the most effective drug NVP-LBH589 in vivo in comparison to placebo using the chimeric mouse model. The NVP-LBH589 dose of 25 mg/kg (5 d/wk) was selected according to a study testing different iv doses of NVP-LAQ824 between 5 and 100 mg/kg (5 d/wk) in a similar chimeric mouse model using the human colon cancer cell line HCT 116. In vivo data for NVP-LBH589 using human prostate carcinoma cell PC-3 xenografts became available only after completion of our study, and showed tumor reduction at a dose of 10 mg/kg per day. In our experiments, NVP-LBH589 significantly reduced tumor mass in comparison to placebo and potentiated the efficacy of gemcitabine. In accordance with our observations, Gahr et al and Piacentini et al showed that a combination with gemcitabine potentiated the in vitro effects of trichostatin A in pancreatic cancer cells, demonstrating a synergistic effect between both agents. This phenomenon has been shown for in vitro cotreatment with SAHA, too, where the compound rendered pancreatic cancer cells sensitive to the inhibitory and proapoptotic effects of gemcitabine. In human breast cancer cell lines SKBR-3 and BT-474, NVP-LAQ824 also enhanced gemcitabine-induced apoptosis in vitro. For head and neck squamous carcinoma cells, the combination of NVP-LAQ824 with gemcitabine was more effective in vitro than a combination with docetaxel, paclitaxel, or cisplatin, especially when the cytotoxic agent was used first for 24 h followed by 48 h of NVP-LAQ824. Unfortunately, in the first recently published randomized, double-blind, placebo-controlled multicenter-phase II trial, gemcitabine plus benzamide HDACI CI-994 (N-acetyldinaline) showed no advantage over gemci-tabine alone in patients with advanced pancreatic cancer. In this study, a total of 174 patients received combination therapy (CI-994, 6 mg/m2 per day, day 1-21 plus gemcitabine, 1000 mg/m2, day 1, 8 and 15 each 28-d cycle) or placebo plus gemcitabine (1000 mg/m2, day 1, 8 and 15 each 28-d cycle). Median survival was 194 d (combination therapy) vs 214 d (gemcitabine) (P = 0.908). The objective response rate was 12% vs 14% when investigator-assessed and 1% vs 6%, respectively, when assessed centrally. Time to treatment failure did not differ between the two arms (P = 0.304). Quality of life scores at 2 mo were worse with the combination than with gemcitabine alone. Pain response rates were similar between the two groups. There was an increased incidence of neutropenia and thrombocytopenia with combination therapy. However, it is currently unknown whether these clinical observations are also true for the hydroxamic acids class of HDACIs. In addition, recent in vitro and in vivo data have shown synergistic effects of trichostatin A in combination with DNA methyltransferase inhibitors azacytidine and zebularine and proteasome inhibitor PS-341, suggesting alternative combination partners for HDACIs. Whereas upregulation of tumor suppressors DUSP6 and MUC 2 is the proposed mechanism for the additional effect of DNA methyltransferase inhibitors, it is inactivation of NFkappaB signalling, downregulation of anti-apoptotic Bcl-xL and disruption of MAP kinase pathway for combination with the proteasome inhibitor PS-341.
Regarding side effects of the different drugs used in our studies, there was no significant additional weight loss in the COMBO group as compared to placebo. Moreover, NVP-LBH589 alone only induced additional weight loss in the HPAF-2 cell experiment. Weight loss in general was apparently more pronounced in the L3.6pl than in the HPAF-2 cell experiment. This may be due to the fact that L3.6pl cells are a selected variant of COLO-357 cells with increased metastatic potential. Regarding other studies, weight loss of animals was not previously reported for NVP-LAQ824, but for NVP-LBH589.
In order to assess in vivo anti-tumoral drug mechanisms, paraffin sections of mouse tumors were stained with hematoxylin-eosin (H&E), MIB-1 (prolife-ration marker) and TUNEL (apoptosis marker). Treatment with NVP-LBH589 and COMBO slightly reduced proliferation (reduced MIB-1 staining) and slightly induced apoptosis (increased TUNEL-staining) in HPAF-2 cell bearing mice, whereas proliferation was not decreased and apoptosis only slightly increased in L3.6pl cell bearing mice. Surprisingly, the calculated numbers were much smaller than expected from the in vitro experiments. This might be derived from the fact that other pathways, like inhibition of angiogenesis, which we were unable to study in our model due to insufficient tissue quality, may be more important for NVP-LBH589 action in the in vivo setting.
Our findings suggest that NVP-LBH589 and NVP-LAQ824 are active against human pancreatic cancer cells in vitro, mainly by inhibition of proliferation and induction of apoptosis. NVP-LBH589 is also active in the in vivo setting, although the precise mechanism of drug action is not yet completely understood. Therefore, a clinical study testing NVP-LBH589 for the treatment of pancreaticobiliary cancer has just been initiated at our department.
Pancreatic adenocarcinoma is essentially an incurable disease, with mortality closely approaching incidence. Single agent gemcitabine is currently considered the standard of care for the treatment of inoperable pancreatic cancer, providing a small but sizable benefit in survival and palliation of symptoms.
In the past ten years, several molecular-targeting agents have been introduced in the clinical setting. Despite promising results in phase II studies, randomized clinical trials exploring the new compounds, such as matrix-metalloprotease-inhibitors (MMPI), farnesyl transferase inhibitors (FTI), signal transduction inhibitors, and angiogenesis inhibitors, either alone or in combination with gemcitabine have been largely disappointing. Polo-like kinase 1 (PLK-1), death receptor 5 (DR5), and histondeacetylase (HDAC) inhibitors are currently under clinical evaluation as new treatment options.
Innovations and breakthroughs
In 2003, fixed-dose-rate (FDR) gemcitabine (1500 mg/m2 at 10 mg/m2 per minute) improved median survival time from 5.0 mo in the standard arm to 8.0 mo in a randomized study; However, grade 3 and 4 toxicity increased significantly. In 2005, investigators of a phase III study found that the gemcitabine-capecitabine combination significantly improved overall survival over gemcitabine alone (hazard ratio 0.80; 95% CI 0.65-0.98; P = 0.026). Recently, a randomized phase III placebo-controlled trial demonstrated that combining gemcitabine with EGFR inhibitor erlotinib was associated with a modest, but statistically significant survival benefit of 15 d.
The aim of our study was to investigate in vitro and in vivo treatment with the histone deacetylase inhibitors NVP-LAQ824 and NVP-LBH589 in pancreatic cancer. Our findings suggested that NVP-LBH589 and NVP-LAQ824 are active against human pancreatic cancer in vitro. In addition, NVP-LBH589 demonstrated significant in vivo activity and potentiated the efficacy of gemcitabine.
Histones (positively charged proteins) are the major components of chromatin. Histone acetylation and deacetylation modulate chromosome structure and regulate gene transcription. Two families of enzymes, histone acetyltransferases (HATs) and histone deacetylases (HDACs), activate and repress gene expression, respectively. Aberrant HAT or HDAC activity is associated with various epithelial and hematologic cancers. HDACs may play an important role in human oncogenesis through HDAC-mediated gene silencing and interaction of HDACs with proteins involved in tumorigenesis. HDAC inhibition could potentially restore normal processes in transformed cells without affecting normal cells.
This paper addresses the use of histone deacetylase inhibitors in the treatment of pancreatic cancer in vitro and in vivo. It represents an important experimental assessment of novel agents in the treatment of a cancer for which effective therapy is currently lacking. It’s a very interesting paper.
Supported by Novartis, No. 934000-258
Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ. Cancer statistics, 2005.CA Cancer J Clin. 2005;55:10-30.
Lockhart AC, Rothenberg ML, Berlin JD. Treatment for pancreatic cancer: current therapy and continued progress.Gastroenterology. 2005;128:1642-1654.
Carpelan-Holmstrom M, Nordling S, Pukkala E, Sankila R, Luttges J, Kloppel G, Haglund C. Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry.Gut. 2005;54:385-387.
Cardenes HR, Chiorean EG, Dewitt J, Schmidt M, Loehrer P. Locally advanced pancreatic cancer: current therapeutic approach.Oncologist. 2006;11:612-623.
Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.J Clin Oncol. 1997;15:2403-2413.
Tempero M, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochster H, Lenzi R, Abbruzzese J. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma.J Clin Oncol. 2003;21:3402-3408.
Cunningham D, Chau I, Stocken D, Davies C, Dunn J, Valle J, Smith D, Steward W, Harper P, Neoptolemos J. Phase III randomised comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer.EJC Supplements. 2005;3:4.
Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.J Clin Oncol. 2007;25:1960-1966.
Philip PA, Benedetti J, Fenoglio-Preiser C, Zalupski M, Lenz H, O’Reilly E, Wong R, Atkins J, Abruzzese J, Blanke C. Phase III study of gemcitabine plus cetuximab versus gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma: SWOG S0205 study.Journal of Clinical Oncology. 2007;ASCO Annual Meeting Proceedings Part I 2007; 25:LBA4509.
Kindler HL, Friberg G, Singh DA, Locker G, Nattam S, Kozloff M, Taber DA, Karrison T, Dachman A, Stadler WM. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer.J Clin Oncol. 2005;23:8033-8040.
Kindler HL, Niedzwiecki D, Hollis D, Oraefo E, Schrag D, Hurwitz H, McLeod HL, Mulcahy MF, Schilsky RL, Goldberg RM. A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB).Journal of Clinical Oncology. 2007;ASCO Annual Meeting Proceedings Part I 2007; 25:4508.
Hess-Stumpp H. Histone deacetylase inhibitors and cancer: from cell biology to the clinic.Eur J Cell Biol. 2005;84:109-121.
Budillon A, Bruzzese F, Di Gennaro E, Caraglia M. Multiple-target drugs: inhibitors of heat shock protein 90 and of histone deacetylase.Curr Drug Targets. 2005;6:337-351.
Remiszewski SW, Sambucetti LC, Bair KW, Bontempo J, Cesarz D, Chandramouli N, Chen R, Cheung M, Cornell-Kennon S, Dean K. N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824).J Med Chem. 2003;46:4609-4624.
George P, Bali P, Annavarapu S, Scuto A, Fiskus W, Guo F, Sigua C, Sondarva G, Moscinski L, Atadja P. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.Blood. 2005;105:1768-1776.
Atadja P, Gao L, Kwon P, Trogani N, Walker H, Hsu M, Yeleswarapu L, Chandramouli N, Perez L, Versace R. Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824.Cancer Res. 2004;64:689-695.
Edwards A, Li J, Atadja P, Bhalla K, Haura EB. Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells.Mol Cancer Ther. 2007;6:2515-2524.
Giles F, Fischer T, Cortes J, Garcia-Manero G, Beck J, Ravandi F, Masson E, Rae P, Laird G, Sharma S. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies.Clin Cancer Res. 2006;12:4628-4635.
Rowinsky EK, Pacey S, Patnaik A, O’Donnell A, Mita MM, Atadja P, Peng B, Dugan M, Scott JW, De Bono JS. A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of a novel histone deacetylase (HDAC) inhibitor LAQ824 in patients with advanced solid tumors.J Clin Oncol. 2004;22:abstract 3022 (ASCO 2004).
Ottmann OG, Deangelo DJ, Stone DJ, Pfeifer H, Lowenberg B, Atadja P, Peng B, Scott JW, Dugan M, Sonneveld P. A Phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of a novel histone deacetylase inhibitor LAQ824 in patients with hematologic malignancies.J Clin Oncol. 2004;22:3024.
Sharma S, Vogelzang NJ, Beck J, Patnaik A, Mita M, Dugan M, Hwang A, Masson E, Culver KW, Prince H. Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of LBH589, a novel deacetylase (DAC) inhibitor given intravenously on a new once weekly schedule.J Clin Oncol. 2007;25:14019.
Prince HM, George D, Patnaik A, Mita M, Dugan M, Butterfoss D, Masson E, Culver KW, Burris HA, Beck J. Phase I study of oral LBH589, a novel deacetylase (DAC) inhibitor in advanced solid tumors and non-hodgkin’s lymphoma.J Clin Oncol. 2007;25:3500.
Ryu B, Jones J, Blades NJ, Parmigiani G, Hollingsworth MA, Hruban RH, Kern SE. Relationships and differentially expressed genes among pancreatic cancers examined by large-scale serial analysis of gene expression.Cancer Res. 2002;62:819-826.
Bruns CJ, Harbison MT, Kuniyasu H, Eue I, Fidler IJ. In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice.Neoplasia. 1999;1:50-62.
Schoumacher RA, Ram J, Iannuzzi MC, Bradbury NA, Wallace RW, Hon CT, Kelly DR, Schmid SM, Gelder FB, Rado TA. A cystic fibrosis pancreatic adenocarcinoma cell line.Proc Natl Acad Sci USA. 1990;87:4012-4016.
Meck RA, Clubb KJ, Allen LM, Yunis AA. Inhibition of cell cycle progression of human pancreatic carcinoma cells in vitro by L-(alpha S, 5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid, Acivicin (NSC 163501).Cancer Res. 1981;41:4547-4553.
Sipos B, Moser S, Kalthoff H, Torok V, Lohr M, Kloppel G. A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform.Virchows Arch. 2003;442:444-452.
Tannapfel A, Geissler F, Kockerling F, Katalinic A, Hauss J, Wittekind C. Apoptosis and proliferation in relation to histopathological variables and prognosis in hepatocellular carcinoma.J Pathol. 1999;187:439-445.
Tannapfel A, Hahn HA, Katalinic A, Fietkau RJ, Kuhn R, Wittekind CW. Prognostic value of ploidy and proliferation markers in renal cell carcinoma.Cancer. 1996;77:164-171.
Natoni F, Diolordi L, Santoni C, Gilardini Montani MS. Sodium butyrate sensitises human pancreatic cancer cells to both the intrinsic and the extrinsic apoptotic pathways.Biochim Biophys Acta. 2005;1745:318-329.
Garcia-Morales P, Gomez-Martinez A, Carrato A, Martinez-Lacaci I, Barbera VM, Soto JL, Carrasco-Garcia E, Menendez-Gutierrez MP, Castro-Galache MD, Ferragut JA. Histone deacetylase inhibitors induced caspase-independent apoptosis in human pancreatic adenocarcinoma cell lines.Mol Cancer Ther. 2005;4:1222-1230.
Sato N, Ohta T, Kitagawa H, Kayahara M, Ninomiya I, Fushida S, Fujimura T, Nishimura G, Shimizu K, Miwa K. FR901228, a novel histone deacetylase inhibitor, induces cell cycle arrest and subsequent apoptosis in refractory human pancreatic cancer cells.Int J Oncol. 2004;24:679-685.
Gahr S, Ocker M, Ganslmayer M, Zopf S, Okamoto K, Hartl A, Leitner S, Hahn EG, Herold C. The combination of the histone-deacetylase inhibitor trichostatin A and gemcitabine induces inhibition of proliferation and increased apoptosis in pancreatic carcinoma cells.Int J Oncol. 2007;31:567-576.
Moore PS, Barbi S, Donadelli M, Costanzo C, Bassi C, Palmieri M, Scarpa A. Gene expression profiling after treatment with the histone deacetylase inhibitor trichostatin A reveals altered expression of both pro- and anti-apoptotic genes in pancreatic adenocarcinoma cells.Biochim Biophys Acta. 2004;1693:167-176.
Cecconi D, Scarpa A, Donadelli M, Palmieri M, Hamdan M, Astner H, Righetti PG. Proteomic profiling of pancreatic ductal carcinoma cell lines treated with trichostatin-A.Electrophoresis. 2003;24:1871-1878.
Arnold NB, Arkus N, Gunn J, Korc M. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer.Clin Cancer Res. 2007;13:18-26.
Juan LJ, Shia WJ, Chen MH, Yang WM, Seto E, Lin YS, Wu CW. Histone deacetylases specifically down-regulate p53-dependent gene activation.J Biol Chem. 2000;275:20436-20443.
Blagosklonny MV, Trostel S, Kayastha G, Demidenko ZN, Vassilev LT, Romanova LY, Bates S, Fojo T. Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors.Cancer Res. 2005;65:7386-7392.
Donadelli M, Costanzo C, Faggioli L, Scupoli MT, Moore PS, Bassi C, Scarpa A, Palmieri M. Trichostatin A, an inhibitor of histone deacetylases, strongly suppresses growth of pancreatic adenocarcinoma cells.Mol Carcinog. 2003;38:59-69.
Tran H, TShoaf SL. Improved efficacy with sequential use of histone deacetylase inhibitor, LAQ824, with common chemotherapeutic agents in head and neck squamous carcinoma cell lines.Proc Amer Assoc Cancer Res. 2005;46:5095.
Fuino L, Bali P, Wittmann S, Donapaty S, Guo F, Yamaguchi H, Wang HG, Atadja P, Bhalla K. Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B.Mol Cancer Ther. 2003;2:971-984.
Bluethner T, Niederhagen M, Caca K, Serr F, Witzigmann H, Moebius C, Mossner J, Wiedmann M. Inhibition of histone deacetylase for the treatment of biliary tract cancer: a new effective pharmacological approach.World J Gastroenterol. 2007;13:4761-4770.
Catley L, Weisberg E, Tai YT, Atadja P, Remiszewski S, Hideshima T, Mitsiades N, Shringarpure R, LeBlanc R, Chauhan D. NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma.Blood. 2003;102:2615-2622.
Bhalla KN, Nimmanapalli R, Fuino L, Tao J, Lee H. Histone deacetylase inhibitor LAQ824 down regulates BCR-ABL levels and induces apoptosis of imatinib mesylate -sensitive or -refractory BCR-ABL positive human leukemia cells.Proc Am Soc Clin Oncol. 2003;22:2322.
Rosato RR, Almenara JA, Maggio SC, Atadja P, Dent P, Grant S. Potentiation of LAQ824-mediated lethality by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells proceeds through an XIAP- and reactive oxygen species (ROS)-dependent mechanism.Proc Amer Assoc Cancer Res. 2005;46:5327.
Maiso P, Carvajal-Vergara X, Ocio EM, Lopez-Perez R, Mateo G, Gutierrez N, Atadja P, Pandiella A, San Miguel JF. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.Cancer Res. 2006;66:5781-5789.
Catley L, Weisberg E, Kiziltepe T, Tai YT, Hideshima T, Neri P, Tassone P, Atadja P, Chauhan D, Munshi NC. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells.Blood. 2006;108:3441-3449.
Fiskus W, Pranpat M, Bali P, Balasis M, Kumaraswamy S, Boyapalle S, Rocha K, Wu J, Giles F, Manley PW. Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells.Blood. 2006;108:645-652.
Qian DZ, Kato Y, Shabbeer S, Wei Y, Verheul HM, Salumbides B, Sanni T, Atadja P, Pili R. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.Clin Cancer Res. 2006;12:634-642.
Piacentini P, Donadelli M, Costanzo C, Moore PS, Palmieri M, Scarpa A. Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation.Virchows Arch. 2006;448:797-804.
Richards DA, Boehm KA, Waterhouse DM, Wagener DJ, Krishnamurthi SS, Rosemurgy A, Grove W, Macdonald K, Gulyas S, Clark M. Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study.Ann Oncol. 2006;17:1096-1102.
Xu S, Furukawa T, Kanai N, Sunamura M, Horii A. Abrogation of DUSP6 by hypermethylation in human pancreatic cancer.J Hum Genet. 2005;50:159-167.
Yamada N, Hamada T, Goto M, Tsutsumida H, Higashi M, Nomoto M, Yonezawa S. MUC2 expression is regulated by histone H3 modification and DNA methylation in pancreatic cancer.Int J Cancer. 2006;119:1850-1857.
Neureiter D, Zopf S, Leu T, Dietze O, Hauser-Kronberger C, Hahn EG, Herold C, Ocker M. Apoptosis, proliferation and differentiation patterns are influenced by Zebularine and SAHA in pancreatic cancer models.Scand J Gastroenterol. 2007;42:103-116.
Bai J, Demirjian A, Sui J, Marasco W, Callery MP. Histone deacetylase inhibitor trichostatin A and proteasome inhibitor PS-341 synergistically induce apoptosis in pancreatic cancer cells.Biochem Biophys Res Commun. 2006;348:1245-1253.
Bruns CJ, Koehl GE, Guba M, Yezhelyev M, Steinbauer M, Seeliger H, Schwend A, Hoehn A, Jauch KW, Geissler EK. Rapamycin-induced endothelial cell death and tumor vessel thrombosis potentiate cytotoxic therapy against pancreatic cancer.Clin Cancer Res. 2004;10:2109-2119.
Bruell D, Bruns CJ, Yezhelyev M, Huhn M, Muller J, Ischenko I, Fischer R, Finnern R, Jauch KW, Barth S. Recombinant anti-EGFR immunotoxin 425(scFv)-ETA' demonstrates anti-tumor activity against disseminated human pancreatic cancer in nude mice.Int J Mol Med. 2005;15:305-313.